GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2009

Roche’s Initial Phase III Trial Finds Taspoglutide Better than Byetta in Type 2 Diabetes

  • Roche reports that its type 2 diabetes drug, taspoglutide, showed better reduction of HbA1c levels compared to Lilly’s Byetta. The Phase III T-EMERGE 2 trial is the first in Roche’s late-stage program for taspoglutide.

    The study involved 1,189 patient and compared the effects of once-weekly taspoglutide, a glucagon-like peptide-1 (GLP-1) agonist, with twice-daily Byetta. Roche’s T-EMERGE Phase III program will include about 6,000 patients in total. Of the eight trials, four have active comparators including Byetta, sitagliptin, insulin glargine, and pioglitazone.

    Roche exercised its taspoglutide licensing option from Ipsen in 2006. Under the terms of the deal, Roche has exclusive rights to develop and market the drug worldwide, except in Japan, where rights are shared with Teijin, and in France, where Ipsen has retained co-marketing rights.

    Lilly reported Byetta-related revenues of $115.8 million during the third quarter, up 6% on the same period last year. $77.8 million of the total related to revenues from the company’s Byetta partnership with Amylin Pharmaceuticals. Direct product sales by Lilly amounted to $38 million.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?